Format

Send to

Choose Destination
J Alzheimers Dis. 2017;60(3):809-817. doi: 10.3233/JAD-160645.

Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease.

Author information

1
Institute of Pharmaceutical Science, King's College London, London, UK.
2
Department of Psychiatry, University of Oxford, Oxford, UK.
3
Department of Neurology, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland.
4
Department of Old Age Psychiatry & Psychotic Disorders, Medical University of Lodz, Lodz, Poland.
5
Section of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia, Italy.
6
Third Department of Neurology, Memory and Dementia Centre, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
7
Department of Internal and Geriatrics Medicine, INSERM U 1027, Gerontopole, Hôpitaux de Toulouse, Toulouse, France.
8
Clinical and Translational Neuroscience Unit, Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD, USA.
9
Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
10
Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia.
11
National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) for Mental Health at South London and Maudsley NHS Foundation Trust, UK.

Abstract

Lipids such as ceramides and phosphatidylcholines (PC) have been found altered in the plasma of Alzheimer's disease (AD) patients in a number of discovery studies. For this reason, the levels of 6 ceramides and 3 PCs, with different fatty acid length and saturation levels, were measured in the plasma from 412 participants (AD n = 205, Control n = 207) using mass spectrometry coupled with ultra-performance liquid chromatography. After this, associations with AD status, brain atrophy, and age-related effects were studied. In the plasma of AD participants, cross-sectional analysis revealed elevated levels of three ceramides (Cer16:0 p < 0.01, Cer18:0 p < 0.01, Cer24:1 p < 0.05). In addition, two PCs in AD plasma (PC36:5 p < 0.05, PC38:6 p < 0.05) were found to be depleted compared to the control group, with PC36:5 also associating with hippocampal atrophy (p < 0.01). Age-specific analysis further revealed that levels of Cer16:0, Cer18:0, and Cer20:0 were associated with hippocampal atrophy only in younger participants (age < 75, p < 0.05), while all 3 PCs did so in the older participants (age > 75, p < 0.05). PC36:5 was associated with AD status in the younger group (p < 0.01), while PC38:6 and 40:6 did so in the older group (p < 0.05). In this study, elevated ceramides and depleted PCs were found in the plasma from 205 AD volunteers. Our findings also suggest that dysregulation in PC and ceramide metabolism could be occurring in different stages of AD progression.

KEYWORDS:

Alzheimer’s disease; brain atrophy; ceramide; phosphatidylcholine

PMID:
27911300
PMCID:
PMC5676755
DOI:
10.3233/JAD-160645
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for IOS Press Icon for PubMed Central
Loading ...
Support Center